Trial Profile
Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol (Primary) ; Estradiol (Primary) ; Ethinylestradiol (Primary) ; Medroxyprogesterone (Primary) ; Norgestimate (Primary) ; Progesterone (Primary)
- Indications Primary ovarian insufficiency
- Focus Therapeutic Use
- Acronyms HOPE
- 18 Mar 2019 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 18 Mar 2019 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 18 Mar 2019 Status changed from recruiting to withdrawn prior to enrolment.